Neuroprotection, Neuroenhancement, and Neuroregeneration
Ophthalmology Science is pleased to announce its latest virtual special issue “Neuroprotection, Neuroenhancement, and Neuroregeneration,” which we hope will propel these fields forward by highlighting advances in preclinical research and early-stage clinical trials geared towards preserving and restoring vision in neurodegenerative diseases of the visual pathway.
Guest edited by Adriana Di Polo, PhD (University of Montreal), Thomas Johnson III, MD, PhD (Johns Hopkins University School of Medicine), Jose-Alain Sahel, MD (University of Pittsburgh School of Medicine), and Joel S. Schuman, MD (New York University Grossman School of Medicine), this special issue will focus on rigorous preclinical research that identifies mechanistically novel targets or approaches to augmenting neuronal survival and function or replacement, and large animal models are of particular interest. We also seek well designed early stage (phase I and II) clinical trials that evaluate neuroprotection and/or neuroenhancement in patients with retinal neurodegeneration or optic neuropathy.
We are also excited to announce that open access fees will be waived for this special issue. The deadline for first round submissions is June 30, 2023. An In Press version of all accepted papers will publish online within 3 to 5 days.
Interested authors should submit their papers via Editorial Manager and choose the Article Type “VSI: Neuroprotection.”
- Neurodegenerative conditions that affect the retina and optic nerve cause irreversible vision loss in hundreds of millions of people worldwide. Therapeutic interventions to slow or halt disease progression exist for a subset of these conditions; however, clinical barriers limit the ability to preserve vision in patients with congenital and acquired optic neuropathies or retinal dystrophies and degeneration. The obstacles include late diagnosis, gaps in health care access, suboptimal treatment adherence, incomplete therapeutic responses to existing therapies, and lack of effective treatments for some pathologies.